S-1/A: Aclarion Inc. Announces Offering of Common Stock and Warrants

Aclarion Inc. is set to offer shares of common stock along with Series A and B warrants, and pre-funded warrants in a new public offering.

Summary

• Aclarion Inc. is offering 75,566,750 shares of common stock, along with Series A and B warrants to purchase additional shares.
• The offering also includes pre-funded warrants as an alternative to common stock for purchasers who might exceed beneficial ownership limits.
• Each share of common stock or pre-funded warrant is sold with one Series A warrant and one Series B warrant.
• The assumed combined public offering price is $0.1588 per share and accompanying warrants, and $0.1578 per pre-funded warrant and accompanying warrants.
• Series A warrants have an exercise price of $[***] and are exercisable after shareholder approval, expiring in five years.
• Series B warrants have an exercise price of $[***] and are exercisable after shareholder approval, expiring in two and a half years.
• The offering is being underwritten on a firm commitment basis, with an option for the underwriter to purchase an additional 15% of the offering.
• The company intends to use the net proceeds from this offering to redeem all outstanding shares of its Series B and C Preferred Stock, and for general corporate purposes.

Sentiment

Score: 4

Explanation: The document presents a mix of positive and negative aspects. While the technology and market opportunity are promising, the company faces significant financial and regulatory challenges, including Nasdaq delisting notices and a history of net losses. The need for additional capital raises and the potential for dilution also contribute to a cautious outlook.

Positives

• The offering provides Aclarion with capital to redeem preferred stock and fund operations.
• The inclusion of warrants may attract investors seeking potential future gains.
• The firm commitment underwriting provides certainty of funding.

Negatives

• The offering includes pre-funded warrants, which may reduce the number of common shares issued.
• The exercise of warrants could dilute existing shareholders.
• The company has received deficiency letters from Nasdaq regarding minimum bid price and stockholders equity requirements.

Risks

• The company is not currently in compliance with Nasdaq's minimum bid price and stockholders equity requirements.
• There is no established public trading market for the warrants or pre-funded warrants.
• The company has a history of net losses and may not achieve profitability.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's commercial success depends on market acceptance of its technology.
• The company's products are currently compatible with a limited number of MRI scanners.
• The company may be unable to obtain, maintain, protect, enforce and defend its intellectual property.
• The company may be unable to compete successfully with other diagnostic options for low back pain.
• The company may be unable to obtain adequate reimbursement for its technology.
• The company's collection, use, storage, disclosure, transfer and other processing of sensitive and personal information could give rise to significant costs, liabilities and other risks.
• The company's current product is supported by a single clinical study at a single clinical center.
• The company may fail to continue to meet the listing standards of The Nasdaq Capital Market.

Future Outlook

The company intends to hold a meeting to obtain shareholder approval for the issuance of shares upon exercise of the warrants as soon as reasonably practicable following the closing of this offering.

Management Comments

• The company intends to take all reasonable measures available to maintain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.

Industry Context

The offering is aimed at addressing the chronic low back pain market, which is a significant healthcare cost in the U.S. The company's technology is intended to improve surgical outcomes and potentially expand to other treatment options.

Comparison to Industry Standards

• The company's technology is positioned as an alternative to the invasive and subjective Provocation Discogram test, which is a current standard for diagnosing discogenic low back pain.
• The company's technology uses Magnetic Resonance Spectroscopy (MRS) to analyze the chemical makeup of intervertebral discs, which is a novel approach compared to standard MRI imaging.
• The company's clinical study results show a 97% success rate when all discs identified as painful by their technology were included in surgical treatment, compared to 54% when such discs were omitted, which is a significant improvement over typical surgical outcomes for discogenic low back pain.
• The company's technology has been selected for participation in a $150 million NIH-funded study, indicating recognition of its potential in the field.

Stakeholder Impact

• Shareholders may experience dilution from the offering and potential future warrant exercises.
• Employees may be affected by the company's financial performance and potential delisting.
• Customers may benefit from the company's technology if it improves treatment outcomes.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company intends to hold a meeting to obtain shareholder approval for the issuance of shares upon exercise of the warrants.
• The company intends to implement a reverse stock split in the near future in order to assist with the Companys compliance with Nasdaqs Bid Price Requirement.
• The company intends to take all reasonable measures available to maintain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.

Key Dates

Keywords

common stock, warrants, pre-funded warrants, public offering, Aclarion, Series A warrants, Series B warrants, Nasdaq, shareholder approval, exercise price, dilution, biomarkers, magnetic resonance spectroscopy, low back pain, discogenic pain